HC Wainwright reissued their buy rating on shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) in a report published on Wednesday. They currently have a $15.00 target price on the biotechnology company’s stock.
“We note that this global study, which randomized lupus nephritis (LN) patients from sites across 27 countries, appears to have experienced a degree of acceleration in enrollment, towards the end, that exceeded even management’s expectation. Having dosed the first patient in AURORA in mid-May 2017, Aurinia had originally projected–during its of last year–full enrollment in 2H18. about one year into patient recruitment (on the date of its 1Q18 results), Aurinia had guided to a 4Q18 enrollment completion. with its 2Q18 release, Aurinia stated that AURORA is running ahead of schedule and that it anticipated, at that time, completing enrollment early 4Q18″.”,” the firm’s analyst commented.
Several other equities research analysts also recently weighed in on the company. Cantor Fitzgerald set a $18.00 target price on Aurinia Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday. BidaskClub raised Aurinia Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, September 6th. ValuEngine raised Aurinia Pharmaceuticals from a hold rating to a buy rating in a research report on Tuesday, August 28th. Finally, Zacks Investment Research downgraded Aurinia Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, August 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $12.11.
AUPH stock traded up $0.23 during trading on Wednesday, reaching $6.33. 18,320 shares of the stock traded hands, compared to its average volume of 416,742. Aurinia Pharmaceuticals has a 52-week low of $4.41 and a 52-week high of $7.60. The company has a market cap of $503.39 million, a PE ratio of -6.74 and a beta of 2.15.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.03). Aurinia Pharmaceuticals had a negative net margin of 12,536.05% and a negative return on equity of 30.34%. The firm had revenue of $0.29 million for the quarter, compared to analysts’ expectations of $0.05 million. equities analysts predict that Aurinia Pharmaceuticals will post -0.71 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the company. Stifel Financial Corp boosted its position in shares of Aurinia Pharmaceuticals by 98.4% in the first quarter. Stifel Financial Corp now owns 21,718 shares of the biotechnology company’s stock worth $113,000 after buying an additional 10,772 shares during the period. DRW Securities LLC purchased a new stake in shares of Aurinia Pharmaceuticals in the first quarter worth about $162,000. Stanley Laman Group Ltd. purchased a new stake in shares of Aurinia Pharmaceuticals in the second quarter worth about $276,000. Creative Planning boosted its position in shares of Aurinia Pharmaceuticals by 8.2% in the second quarter. Creative Planning now owns 171,200 shares of the biotechnology company’s stock worth $964,000 after buying an additional 13,000 shares during the period. Finally, Ironwood Investment Management LLC lifted its stake in shares of Aurinia Pharmaceuticals by 18.0% in the second quarter. Ironwood Investment Management LLC now owns 218,568 shares of the biotechnology company’s stock worth $1,231,000 after acquiring an additional 33,279 shares in the last quarter. 24.92% of the stock is owned by institutional investors.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Featured Article: What is the NASDAQ?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.